Login / Signup

CDK4/6 inhibitors induce replication stress to cause long-term cell cycle withdrawal.

Lisa CrozierReece FoyBrandon L MoueryRobert H WhitakerAndrea CornoChristos SpanosTony LyJeanette Gowen CookAdrian T Saurin
Published in: The EMBO journal (2022)
CDK4/6 inhibitors arrest the cell cycle in G1-phase. They are approved to treat breast cancer and are also undergoing clinical trials against a range of other tumour types. To facilitate these efforts, it is important to understand why a cytostatic arrest in G1 causes long-lasting effects on tumour growth. Here, we demonstrate that a prolonged G1 arrest following CDK4/6 inhibition downregulates replisome components and impairs origin licencing. Upon release from that arrest, many cells fail to complete DNA replication and exit the cell cycle in a p53-dependent manner. If cells fail to withdraw from the cell cycle following DNA replication problems, they enter mitosis and missegregate chromosomes causing excessive DNA damage, which further limits their proliferative potential. These effects are observed in a range of tumour types, including breast cancer, implying that genotoxic stress is a common outcome of CDK4/6 inhibition. This unanticipated ability of CDK4/6 inhibitors to induce DNA damage now provides a rationale to better predict responsive tumour types and effective combination therapies, as demonstrated by the fact that CDK4/6 inhibition induces sensitivity to chemotherapeutics that also cause replication stress.
Keyphrases
  • cell cycle
  • dna damage
  • cell proliferation
  • induced apoptosis
  • clinical trial
  • oxidative stress
  • cell cycle arrest
  • dna repair
  • mental health
  • stress induced
  • drug delivery
  • cell death
  • open label
  • study protocol
  • pi k akt